1. Home
  2. CIX vs PRTA Comparison

CIX vs PRTA Comparison

Compare CIX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CompX International Inc.

CIX

CompX International Inc.

N/A

Current Price

$36.41

Market Cap

473.6M

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.54

Market Cap

458.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CIX
PRTA
Founded
1993
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
473.6M
458.4M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
CIX
PRTA
Price
$36.41
$8.54
Analyst Decision
Hold
Analyst Count
0
6
Target Price
N/A
★ $21.40
AVG Volume (30 Days)
29.3K
★ 337.4K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 5.88%
N/A
EPS Growth
★ 17.04
N/A
EPS
★ 1.06
0.26
Revenue
★ $158,285,000.00
$814,000.00
Revenue This Year
N/A
$758.69
Revenue Next Year
N/A
N/A
P/E Ratio
$35.50
★ $33.27
Revenue Growth
★ 8.46
N/A
52 Week Low
$20.29
$7.73
52 Week High
$40.29
$11.80

Technical Indicators

Market Signals
Indicator
CIX
PRTA
Relative Strength Index (RSI) 55.71 44.91
Support Level $23.61 $8.12
Resistance Level $40.29 $9.29
Average True Range (ATR) 2.28 0.38
MACD -0.24 -0.02
Stochastic Oscillator 35.98 41.50

Price Performance

Historical Comparison
CIX
PRTA

About CIX CompX International Inc.

Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: